title: [Enoxaparin vs. non-fractionated heparin in primary angioplasty of acute myocardial infarction].
abstract: OBJECTIVE
  The objective of this study is to compare the effectiveness of intravenous enoxaparin (ENX) and Non-fractionated Heparin (NFH) in primary angioplasty (PA) of acute myocardial infarction (PA-AMI).
  
  
  METHODS
  A prospective, observational study.
  
  
  METHODS
  A total of 191 patients admitted at the hospital with the diagnosis of Acute Myocardial Infarction (AMI) and treated with primary angioplasty were included. ENX was used in 91 patients (47.6%) and NFH in 100 patients (52.4%). Choice of treatment was based on the operator's opinion. Patients with cardiogenic shock were excluded. The first group received an intravenous bolus of ENX (0.75-1 mg/Kg) and the second one NFH (70-100 u/Kg), depending on whether it was associated with abciximab or not. In-hospital follow-up was performed, evaluating mortality and bleeding complications of both treatments.
  
  
  RESULTS
  In-hospital mortality was 1.1% for the ENX group and 3.3% for NFH one. No significant differences were found in the number of bleeding complications with ENX (4.4%) and NFH (9.0%). There was one subacute thrombosis of stent for the ENX group and 3 thrombosis in the NFH-treated group. No significant differences were found in size of infarction measure with troponin I level (63.1 for ENX and 54.8 for the NFH) or in the left ventricle ejection fraction on hospital discharge (51% for ENX and 49.4% for the NFH).
  
  
  CONCLUSIONS
  Primary angioplasty can be safely sued with the intravenous administration of ENX, no significant differences being found between both treatments in mortality and bleeding complications.
authors.affiliation: Unidad de Hemodinámica y Cardiología Intervencionista, Servicio de Cardiología. Hospital Universitario La Paz, Madrid. España. ggaleote.hulp@salud.madrid.org
authors.forename: Guillermo
authors.initials: G
authors.lastname: Galeote
authors.forename: Raúl
authors.initials: R
authors.lastname: Moreno
authors.forename: Angel
authors.initials: A
authors.lastname: Sánchez-Recalde
authors.forename: Santiago
authors.initials: S
authors.lastname: Jiménez-Valero
authors.forename: Luís
authors.initials: L
authors.lastname: Calvo
authors.forename: Fernando
authors.initials: F
authors.lastname: Rivero
authors.forename: José F
authors.initials: JF
authors.lastname: Gallegos
authors.forename: Estebán
authors.initials: E
authors.lastname: López de Sa
authors.forename: José A
authors.initials: JA
authors.lastname: Sobrino
authors.forename: José L
authors.initials: JL
authors.lastname: López-Sendón
mesh_terms: D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D017984:Enoxaparin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017052:Hospital Mortality; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000627:therapeutic use; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy*; D011183:Postoperative Complications / Q000139:chemically induced / Q000401:mortality / Q000517:prevention & control*; D011446:Prospective Studies; D015607:Stents; D013927:Thrombosis / Q000453:epidemiology / Q000517:prevention & control*
chemical_list: D000911:Antibodies, Monoclonal; D017984:Enoxaparin; D007140:Immunoglobulin Fab Fragments; D006493:Heparin; D000077284:Abciximab